The present disclosure relates to methods and apparatus for augmenting bone defects.
This section provides background information related to the present disclosure and is not necessarily prior art.
Bone damage and/or bone loss can occur, for example, due to disease, trauma, and/or birth defects. Bone implants or augments can be used to repair such damaged bone. Bone augments are often manufactured from metal and have a permanent shape and size, thereby providing only limited restoration of bone stock. A bone augment that can be completely remodeled into bone over time and be modified intraoperatively would be desirable.
This section provides a general summary of the disclosure, and is not a comprehensive disclosure of its full scope or all of its features.
The present teachings provide for a bone augment for repairing a bone defect. The bone augment includes a porous body and a metallic liner. The porous body defines a bore and is configured to be intraoperatively shaped to correspond to the bone defect. The metallic liner is injection molded within the bore such that portions of the liner interlock with pores of the porous body. The metallic liner is operable to mount an implant to the bone augment.
The present teachings also provide for a bone augment for repairing a bone defect that includes a porous body and a metallic liner. The porous body defines a bore and is configured to be intraoperatively shaped to correspond to the bone defect. The metallic liner is secured within the bore.
The present teachings also provide for a bone augment for repairing a bone defect that includes a bone engaging body and an exterior surface. The bone engaging body defines a plurality of pores. The body is configured to be intraoperatively shaped to correspond to the bone defect. An exterior surface of the bone engaging body includes a polymeric reinforcement member mounted thereto. The reinforcement member is operable to be intraoperatively shaped to correspond to the bone defect.
Further areas of applicability will become apparent from the description provided herein. The description and specific examples in this summary are intended for purposes of illustration only and are not intended to limit the scope of the present disclosure.
The drawings described herein are for illustrative purposes only of selected embodiments and not all possible implementations, and are not intended to limit the scope of the present disclosure.
Corresponding reference numerals indicate corresponding parts throughout the several views of the drawings.
Example embodiments will now be described more fully with reference to the accompanying drawings.
A bone augment according to the present teachings is illustrated in
The augment 10 can be made of any suitable porous material, such as a ceramic or coral, which can be remodeled to bone. Suitable corals include coral hydrothermically converted to hydroxyapatite, such as any of the Pro Osteon® family of bone augments by Biomet of Warsaw, Ind., including Pro Osteon® 200R and 500R for example, which have pore sizes of about 200 and 500 microns respectively. Pro Osteon® is offered in various shapes and sizes, such as a square or rectangular block, as illustrated in
As illustrated in
The strengthening component 14 can include any suitable biocompatible component, such as a suitable polymer or non-metal 14A (
With additional reference to
The bore 16 can include any suitable liner operable to provide a mechanical connection with an implant, such as a femoral implant stem. The liner increases the strength of the augment 10 to facilitate support of the implant and prevent the augment from possibly fracturing. As illustrated in
With additional reference to
The first flange 26 and the second flange 28 can be annular flanges or have any suitable shape to restrict rotation of the insert 20 within the bore 16, such as triangular, square, or hexagonal. The shape of the flanges 26 and 28 can be independent of the shape of the bore 16. For example,
As illustrated in
The cap 24 can be mounted to the main body 22 in any suitable manner. For example and with reference to
With additional reference to
The taper base 32 includes a flange 38 at an end thereof that abuts the exterior surface 30 of the augment 10 when the taper base 32 is seated within the bore 16. A cap 40 interlocks with the taper base 32 in any suitable manner, such as through a snap-fit connection between a tab 42 extending from the cap 40 and a recess 47 in the taper base 32. Further, any of the other connection mechanisms described herein can be used, such as those described in
The cap 40 includes a flange 44 that abuts the exterior surface of the augment 10 to secure the taper base 32 within the bore 16 to restrict axial movement of the taper base 32 within the bore 16. The flanges 38 and 44 are positioned proximate to the exterior surface 30 of the augment 10. To accommodate the flanges 38 and 44, a portion of the exterior surface 30 can be cut out using a suitable cutting device, such as a scalpel, knife, or rongeurs, to permit the flanges 38 and 44 to be positioned coplanar with the exterior surface 30. In the alternative, the portion of the exterior surface 30 that is cut out can be made in a manufacturing environment, such as with a mill. The flanges 38 and 44 can also be positioned such that they protrude slightly beyond the exterior surface 30. The flanges 38 and 44 can be annular flanges or have any suitable shape to restrict rotation of the taper base 32 within the bore 16, such as triangular similar to the shape of the flange 26 of
With additional reference to
The augment 50 also includes a reinforcement member 52. The reinforcement member 52 includes a first projection 54 and a second projection 56, each projection 54 and 56 includes an aperture 58 capable of receiving a suitable fastening device, such as a screw 60. The reinforcement member 52 can replace cortical bone, as described further below, and includes a density similar to cortical bone. The reinforcement member 52 can include any suitable biocompatible material, such as one or more metallic or polymeric materials.
Suitable polymers or non-metals include one or more of the following: ultra-high molecular weight polyethylene, pyrocarbon, silicone, polyether ether ketone (“PEEK”), carbon fiber reinforced PEEK (such as PEEK-OPTIMA® from Invibio, Ltd. of the United Kingdom), and/or vitamin E stabilized highly crosslinked polyethylene (HXLPE), such as described in U.S. Pat. No. 7,431,874 and all continuation applications and patents related thereto, which are incorporated herein by reference. An exemplary vitamin E stabilized HXLPE that may be used includes E-Poly or E1™ offered by Biomet of Warsaw, Ind. Suitable metals include, for example, CoCr, titanium, and combinations thereof.
The projections 54 and 56 can be deformed in any suitable manner to match the morphology of a repair site. For example, the projections 54 and 56 can be bent with a suitable instrument (such as pliers or a roll bender, for example), can be pressed into a mold of the implant site, and can be machined during manufacturing to correspond a specific patient's morphology.
The reinforcement member 52 can be mounted to the augment 50 in any suitable matter, such as with injection molding or compression molding. With both injection molding and compression molding, portions of the reinforcement member 52 enter a portion of the pores 12′ to provide a mechanical interlock with the pores 12′. As with the augment 50, the reinforcement member 52 can be machined in order to fit a particular defect site. As further discussed herein, the augment with the reinforcement member 52 mounted thereto can be used to fill an uncontained defect, such as at a peripheral portion of a tibia upper extremity, because the reinforcement member 52 can retain the augment 50 in an uncontained defect through cooperation between the screws 60 and surrounding bone.
As illustrated in
With additional reference to
To shape the body 11, a suitable cutting device, such as a scalpel, saw, or rongeurs, for example, can be used. The shaped augment 10 is secured at the defect site 102 in any suitable manner, such as with a press-fit or suitable fastener, to fill damaged cancellous bone. The composition of the augment 10, particularly Pro Osteon®, permits insertion of a fastener into the augment 10 without pre-drilling. Any suitable implant, such as a femoral implant 106 having a stem 108 and a neck 110 supporting a head 111, can be attached to the augment 10 for support. As illustrated, the stem 108 is inserted into the bore 16 to mate with the metallic insert 20, which secures the stem 108 with a press-fit and/or a Morse taper. During the healing process bone grows into the pores 12 of the augment 10 and the augment 10 is remodeled into the femur 100, except for the metallic insert 20.
The insert 20 is optional. When the insert 20 is not used, the stem 108, or any suitable implant, can be secured within the bore 16 with a suitable fastening device or material, such as poly methyl methacrylate (“PMMA”) bone cement.
With additional reference to
With reference to
The augment 50 and reinforcement member 52 can each be intraoperatively shaped to accommodate the uncontained defect 152 using a suitable cutting device. To shape the body 11′ the cutting device 104, such as a scalpel, saw, or rongeurs, for example, can be used. To shape the reinforcement member 52, a bur, saw, or rongeurs, for example, can be used. The shaped augment 50 is secured at the defect site 152 with the screws 60, which extend through the projections 54 and 56 and into an area of the tibia 150 proximate to the defect 152 having bone of sufficient rigidity to retain the screws 60, such as cortical bone. During the healing process, cancellous bone is permitted to grow into the pores 12′ of the augment 50 and the augment 50 is remodeled into the tibia 150, except for the polymeric reinforcement member 52, the rigidity of which serves to replace the missing cortical bone. Thus, the augment 50 is positioned such that the body 11′ provides a bone engaging surface and the reinforcement 52 provides a exterior surface.
Use of the augments 10 and 50 in the femur 100 and the tibia 150 is for exemplary purposes only. The bone augments 10 and 50 can be used to repair any suitable defect in suitable bone. To accommodate use of the augments 10 and 50 in bones of various different sizes, various sized augments 10 and 50 can be provided.
The foregoing description of the embodiments has been provided for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention. Individual elements or features of a particular embodiment are generally not limited to that particular embodiment, but, where applicable, are interchangeable and can be used in a selected embodiment, even if not specifically shown or described. The same may also be varied in many ways. Such variations are not to be regarded as a departure from the invention, and all such modifications are intended to be included within the scope of the invention.
Number | Name | Date | Kind |
---|---|---|---|
3605123 | Hahn | Sep 1971 | A |
3929971 | Roy | Dec 1975 | A |
4202055 | Reiner et al. | May 1980 | A |
4655777 | Dunn et al. | Apr 1987 | A |
4722870 | White | Feb 1988 | A |
4737411 | Graves, Jr. et al. | Apr 1988 | A |
4769011 | Swaniger | Sep 1988 | A |
4822366 | Bolesky | Apr 1989 | A |
4846839 | Noiles | Jul 1989 | A |
4861733 | White | Aug 1989 | A |
4944757 | Martinez et al. | Jul 1990 | A |
4969896 | Shors | Nov 1990 | A |
4976736 | White et al. | Dec 1990 | A |
5002578 | Luman | Mar 1991 | A |
5084051 | Tormala et al. | Jan 1992 | A |
5137535 | Keller | Aug 1992 | A |
5181928 | Bolesky et al. | Jan 1993 | A |
5186162 | Talish et al. | Feb 1993 | A |
5211160 | Talish et al. | May 1993 | A |
5290313 | Heldreth | Mar 1994 | A |
5348788 | White | Sep 1994 | A |
5455100 | White | Oct 1995 | A |
5487933 | White | Jan 1996 | A |
5552454 | Kretschmann et al. | Sep 1996 | A |
5571193 | Kampner | Nov 1996 | A |
5653765 | McTighe et al. | Aug 1997 | A |
5725592 | White et al. | Mar 1998 | A |
5728510 | White | Mar 1998 | A |
5876459 | Powell | Mar 1999 | A |
5879391 | Slamin | Mar 1999 | A |
5879394 | Ashby et al. | Mar 1999 | A |
5902340 | White et al. | May 1999 | A |
5906644 | Powell | May 1999 | A |
5931871 | Baur et al. | Aug 1999 | A |
5976188 | Dextradeur et al. | Nov 1999 | A |
5977204 | Boyan et al. | Nov 1999 | A |
5986169 | Gjunter | Nov 1999 | A |
6008430 | White | Dec 1999 | A |
6156070 | Incavo et al. | Dec 2000 | A |
6224602 | Hayes | May 2001 | B1 |
6264698 | Lawes et al. | Jul 2001 | B1 |
6264699 | Noiles et al. | Jul 2001 | B1 |
6296667 | Johnson et al. | Oct 2001 | B1 |
6302888 | Mellinger et al. | Oct 2001 | B1 |
6319286 | Fernandez et al. | Nov 2001 | B1 |
6342157 | Hood, III | Jan 2002 | B1 |
6344496 | Niederauer et al. | Feb 2002 | B1 |
6364881 | Apgar et al. | Apr 2002 | B1 |
6376573 | White et al. | Apr 2002 | B1 |
6464728 | Murray | Oct 2002 | B1 |
6518328 | Kumar | Feb 2003 | B2 |
6520994 | Nogarin | Feb 2003 | B2 |
6524342 | Muhlhausler et al. | Feb 2003 | B1 |
6524345 | Valimaa et al. | Feb 2003 | B1 |
6527810 | Johnson et al. | Mar 2003 | B2 |
6565884 | Nimni | May 2003 | B2 |
6626950 | Brown et al. | Sep 2003 | B2 |
6632247 | Boyer et al. | Oct 2003 | B2 |
6706072 | Dwyer et al. | Mar 2004 | B2 |
6716250 | Ganjianpour | Apr 2004 | B2 |
6723129 | Dwyer et al. | Apr 2004 | B2 |
6843805 | Webb et al. | Jan 2005 | B2 |
6843808 | Grundei | Jan 2005 | B2 |
6869450 | Grundei | Mar 2005 | B2 |
6875239 | Gerbec et al. | Apr 2005 | B2 |
6887276 | Gerbec et al. | May 2005 | B2 |
6981991 | Ferree | Jan 2006 | B2 |
7018420 | Grundei | Mar 2006 | B2 |
7097664 | Despres et al. | Aug 2006 | B2 |
7105026 | Johnson et al. | Sep 2006 | B2 |
7122056 | Dwyer et al. | Oct 2006 | B2 |
7156880 | Evans et al. | Jan 2007 | B2 |
7166133 | Evans et al. | Jan 2007 | B2 |
7175664 | Lakin | Feb 2007 | B1 |
7189263 | Erbe et al. | Mar 2007 | B2 |
7192448 | Ferree | Mar 2007 | B2 |
7431874 | Muratoglu et al. | Oct 2008 | B2 |
7435263 | Barnett et al. | Oct 2008 | B2 |
7445639 | Metzger et al. | Nov 2008 | B2 |
7470289 | Brehm | Dec 2008 | B2 |
7497874 | Metzger et al. | Mar 2009 | B1 |
7582092 | Jones et al. | Sep 2009 | B2 |
7691150 | Cronin et al. | Apr 2010 | B2 |
7740662 | Barnett et al. | Jun 2010 | B2 |
7794503 | Daniels et al. | Sep 2010 | B2 |
7854737 | Daniels et al. | Dec 2010 | B2 |
7857858 | Justin et al. | Dec 2010 | B2 |
7909883 | Sidebotham | Mar 2011 | B2 |
7951205 | McCleary et al. | May 2011 | B2 |
8100982 | Heck et al. | Jan 2012 | B2 |
8163028 | Metzger et al. | Apr 2012 | B2 |
8241367 | Justin et al. | Aug 2012 | B2 |
20020004685 | White | Jan 2002 | A1 |
20020143403 | Vaidyanathan et al. | Oct 2002 | A1 |
20030065397 | Hanssen et al. | Apr 2003 | A1 |
20030109878 | Grundei | Jun 2003 | A1 |
20030139818 | Rogers et al. | Jul 2003 | A1 |
20040162619 | Blaylock et al. | Aug 2004 | A1 |
20040243248 | Despres et al. | Dec 2004 | A1 |
20040254646 | Stone et al. | Dec 2004 | A1 |
20050010304 | Jamali | Jan 2005 | A1 |
20050075641 | Singhatat et al. | Apr 2005 | A1 |
20050278034 | Johnson et al. | Dec 2005 | A1 |
20060020346 | Hunter et al. | Jan 2006 | A1 |
20060173550 | Ragbir | Aug 2006 | A1 |
20070021838 | Dugas et al. | Jan 2007 | A1 |
20070088443 | Hanssen et al. | Apr 2007 | A1 |
20070135924 | Verhoogen | Jun 2007 | A1 |
20090149963 | Sekel | Jun 2009 | A1 |
20090306787 | Crabtree et al. | Dec 2009 | A1 |
20100114314 | Lomicka et al. | May 2010 | A1 |
20100145452 | Blaylock et al. | Jun 2010 | A1 |
20100241239 | Smith | Sep 2010 | A1 |
20110160870 | Baumgartner et al. | Jun 2011 | A1 |
20110178604 | Porter | Jul 2011 | A1 |
20110196503 | Anapliotis et al. | Aug 2011 | A1 |
20110208189 | Faccioli et al. | Aug 2011 | A1 |
Entry |
---|
“Artificial Bone Grafts:Pro Osteon”, http://www.arthroscopy.com/sp12013.htm, Copyright 1999, 4 sheets. |
Bio-Medicine; Pro Osteon Bone Graft Substitutes (2pgs). |
Pro Osteon® 200R Bone Graft Substitute, Medcompare, Copyright 2003-2009, (2pgs). |
Pro Osteon® 500R; Biomet, Copyright 2009 (1 pg). |
Pro Osteon® Biomet 200R (1pg). |
The Natural Facts About Pro Osteon Implant 500, Interpore International (6pgs). |
Number | Date | Country | |
---|---|---|---|
20110202141 A1 | Aug 2011 | US |